Patent
Anti-angiogenic compositions and methods of use
Reads0
Chats0
TLDR
In this article, an anti-angiogenic factor and a polymeric carrier were used for embolization of blood vessels and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions.Abstract:
The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids and derivatives thereof, and paclitaxel. Also provided are methods for embolizing blood vessels, and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions.read more
Citations
More filters
Patent
Coated implantable medical device
TL;DR: A coated implantable medical device as discussed by the authors includes a structure 12 adapted for introduction into the vascular system, esophagus, trachea, colon, biliary tract, or urinary tract.
Patent
Therapeutic inhibitor of vascular smooth muscle cells
TL;DR: In this paper, the authors present methods for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent.
Patent
Medical devices and applications of polyhydroxyalkanoate polymers
TL;DR: In this paper, the degradation times of polyhydroxyalkanoates are controlled under physiological conditions, and the degradation rates are controlled with less than one year under certain physiological conditions.
Patent
Silver implantable medical device
Anthony O. Ragheb,Brian L. Bates,Neal E. Fearnot,Thomas A. Osborne,Thomas G. Kozma,Joseph W. Roberts,William D. Voorhees +6 more
TL;DR: In this paper, a coronary stent implantable medical device is defined as a structure 12 adapted for introduction into the vascular system, esophagus, trachea, colon, biliary tract, or urinary tract.
Patent
Drug coating with topcoat
Ni Ding,Michael N. Helmus +1 more
TL;DR: In this paper, a method for a coating an implantable device or prosthesis is described, which includes an undercoat of polymeric material containing an amount of biologically active material, particularly heparin, dispersed therein.
References
More filters
Patent
Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
TL;DR: In this paper, the authors provided compositions for the in vivo delivery of substantially water insoluble pharmacologically active agents (such as the anticancer drug taxol) in which the pharmacological active agent is delivered in a soluble form or in the form of suspended particles.
Journal ArticleDOI
Defining coronary restenosis. Newer clinical and angiographic paradigms.
Richard E. Kuntz,Donald S. Baim +1 more
Journal ArticleDOI
Coating particles with a block co-polymer (poloxamine-908) suppresses opsonization but permits the activity of dysopsonins in the serum
TL;DR: It is demonstrated that organ-specific receptors, opsonin activities and plasma dysopsonins regulate the in vivo clearance of particulate materials from the circulation by modulating particle clearance by effectively blocking opsonization but still allowing for Dysopsonization.
Journal ArticleDOI
Human skin fibroblast collagenase inhibitor. Purification and biochemical characterization.
G P Stricklin,H G Welgus +1 more
TL;DR: A chromatographically and immunologically identical collagenase inhibitor was partially purified from human serum, suggesting the possibility that the fibroblast-derived inhibitor and the previously reported serum beta 1-anticollagenase are similar, if not identical, proteins.
Patent
Process for the preparation of taxol and 10-deacetyltaxol
TL;DR: Taxol, 10-deacetyltaxol and other taxane derivatives are prepared from naturally occurring taxane-7-xylosides by the oxidative cleavage of the 7-Xyloside moieties as mentioned in this paper.